Hims & Hers Health shares gain more than 3% after strong revenue growth and subscriber gains outweigh renewed operating losses
Hims & Hers Health Inc (HIMS) advanced 3.02% after delivering strong revenue growth and subscriber gains in its latest quarter, even as the company swung back to operating losses. The rebound looks limited, with the stock still trading below all key moving averages and bearish momentum signals persisting.
Highlights
- Hims & Hers Health posted a $66.1 million operating loss and a $33 million net loss for the third quarter of 2026, reversing its prior-year profit.
- Revenue increased 49% year-over-year to $890.4 million and subscribers reached 2.8 million, with the company expanding its product lineup and obtaining access to Zepbound.
- Shares of Hims & Hers Health trade below key technical levels with strong bearish signals, an expected range of $16.43 to $19.72, and a very high probability of a downward move in the next five days.
Subscriber growth and new products amid widening operating loss
Hims & Hers Health reported a return to operating losses in the third quarter of 2026, posting a $66.1 million operating loss and a net loss of $33 million, reversing its prior-year profit. Revenue climbed 49% year-over-year to $890.4 million, and subscriber numbers rose 13% to 2.8 million despite a quarterly decline due to reduced marketing and a brand transition. The company expanded its product lineup by launching the Peptides+ platform and secured access to Eli Lilly's Zepbound, while a company officer filed to sell 3,518 Class A shares under a Rule 10b5-1 plan.
Persistent bearish momentum as price holds below key averages
Hims & Hers Health is trading below all major moving averages, with the price at $18.08 under the MA-20 at $24.72, MA-50 at $27.22, and MA-200 at $26.59. This configuration highlights sustained selling pressure and a clearly bearish setup across short, medium, and long-term trends. The nearest resistance is at $18.54, and support stands at $17.15, with the Ichimoku Kijun level at $23.71 reinforcing the downward technical bias. Momentum indicators remain strongly bearish: the MACD is negative, ADX points to ongoing selling, and the RSI, Stochastic RSI, and CCI all indicate an oversold condition. The Bull/Bear Power (BBP) is deeply negative at -3.27, and the Awesome Oscillator remains below zero, reflecting seller dominance. Trading is occurring near session highs after a 5.58% intraday gap and 3.02% advance, but short-term technical signals still point to lingering downward momentum amid elevated intraday volatility of 8.10%.
Earlier, analysts noted that Hims & Hers Health continued to exhibit persistent downside momentum and technical fragility despite recent strategic initiatives. The current analysis reinforces this assessment, with bearish pressures still in control and the prevailing risk centered on whether the stock can hold support at $17.15 over the coming sessions.